MDMA-Assisted Therapy Shows Promise in Treating PTSD, Study Reveals
Results of a study published on Thursday show that MDMA-assisted therapy could be an effective treatment for post-traumatic stress disorder (PTSD). Conducted by MAPS Public Benefit Corporation, a company focused on developing prescription psychedelics, the study aims to submit the findings to the Food and Drug Administration (FDA) for approval to market MDMA as a treatment for PTSD when combined with talk therapy.
With approximately 5 percent of the adult population in the United States affected by PTSD each year, the potential approval of MDMA-assisted therapy would be a significant breakthrough. Currently, available conventional therapies and medications only provide relief for around 50 percent of patients, underscoring the need for innovative treatment options.
Berra Yazar-Klosinski, the senior author of the study, emphasized the hope that MDMA-assisted therapy brings to PTSD patients. The therapy could be the first new treatment for the disorder in over two decades and offers a glimmer of hope for those struggling with its debilitating symptoms.
Dr. Stephen Xenakis, a psychiatrist and executive director of the American Psychedelic Practitioners Association, who was not directly involved in the study, acknowledged the limitations of current therapies and medications when it comes to effectively treating PTSD. The potential approval of MDMA-assisted therapy offers a much-needed alternative for patients seeking relief from the disorder.
MDMA, also known as ecstasy or Molly, is a psychoactive drug that affects mood and perception. When used in a controlled therapeutic setting, it has shown promising results in reducing the symptoms of PTSD. The drug acts by increasing the release of certain brain chemicals associated with positive emotions and social connection, facilitating an optimal state for therapy.
MAPS Public Benefit Corporation remains committed to further research and is hopeful that the positive results from this study will pave the way for FDA approval of MDMA-assisted therapy. If approved, it would provide patients with a much-needed breakthrough treatment option for PTSD, potentially transforming lives and offering renewed hope for thousands of individuals across the country.
As the conversation around psychedelics continues to gain momentum, further research and clinical trials are necessary to better understand the potential benefits and risks associated with MDMA-assisted therapy. With more people speaking out about their struggles with PTSD and the limitations of currently available treatments, the need for effective alternatives becomes even more pronounced.
“Musicaholic. Thinker. Extreme travel trailblazer. Communicator. Total creator. Twitter enthusiast.”